Last update March 9, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Rofecoxib in other languages or writings:
Rofecoxib belongs to this group or family:
Main tradenames from several countries containing Rofecoxib in its composition:
|Tmax||2 - 4||hours|
|M/P ratio||0.25 (0.16 - 0.32)||-|
|Relative Dose||2.1 (1.8 - 3.2)||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Non-steroidal anti-inflammatory drug (NSAID) that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme.
It was administered orally for the treatment of osteoarthritis, rheumatoid arthritis, acute pain, dysmenorrhea, and migraine until its withdrawal from the market.
It is still available for topical cutaneous application.
Excreted in negligible amounts through breastmilk (Gardiner 2005).
It was withdrawn from the global market in 2004 due to a high risk of cardiovascular toicity (Myocardial infarction, ictus) in people that used it frequently.
Use of preparations for topical application would be compatible with breastfeeding.